Meyer Handelman Co. Sells 50,802 Shares of Pfizer Inc. $PFE

Meyer Handelman Co. lowered its position in Pfizer Inc. (NYSE:PFE) by 4.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,186,815 shares of the biopharmaceutical company’s stock after selling 50,802 shares during the quarter. Meyer Handelman Co.’s holdings in Pfizer were worth $29,552,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. State Street Corp lifted its position in Pfizer by 0.9% during the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after acquiring an additional 2,786,098 shares during the last quarter. Northern Trust Corp grew its holdings in Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after purchasing an additional 869,175 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of Pfizer by 1.9% during the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock worth $1,255,860,000 after purchasing an additional 897,786 shares in the last quarter. Legal & General Group Plc increased its position in shares of Pfizer by 8.6% during the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after purchasing an additional 3,296,415 shares in the last quarter. Finally, Amundi boosted its position in shares of Pfizer by 10.8% in the 3rd quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock worth $1,096,380,000 after purchasing an additional 4,043,413 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $28.08 on Wednesday. The business has a fifty day moving average of $26.94 and a 200 day moving average of $25.75. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $28.31. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm has a market capitalization of $159.67 billion, a price-to-earnings ratio of 20.65 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Royal Bank Of Canada initiated coverage on Pfizer in a research note on Tuesday, February 24th. They set an “underperform” rating and a $25.00 target price on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. Guggenheim boosted their price target on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Barclays assumed coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective on the stock. Finally, TD Cowen reiterated a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.19.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Fresh real‑world data from Pfizer’s Swedish observational study on Ibrance (palbociclib) is being framed as a positive signal for the drug’s real‑world effectiveness and market durability, which could support oncology revenue expectations. Pfizer’s Swedish Ibrance Study
• Positive Sentiment: Heightened media and retail investor attention around Pfizer’s GLP‑1/weight‑loss pipeline (including coverage noting share strength despite a high‑profile “pass” comment) is boosting sentiment—investors are pricing potential upside from a once‑monthly treatment. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Dividend appeal remains a tailwind for income investors—Pfizer is regularly cited among large caps with attractive dividends, supporting buy‑and‑hold interest. Pfizer – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Retail and institutional attention is elevated (high search/coverage), which can amplify moves but doesn’t guarantee direction — monitor whether flow sustains. Investors Heavily Search Pfizer Inc. (PFE)
• Neutral Sentiment: Broader sector moves (e.g., large deals and AI partnerships at peers) are reshaping investor rotation in healthcare but are not direct Pfizer catalysts; they do, however, affect relative valuation dynamics. Eli Lilly Ramps Up AI Ambitions
• Negative Sentiment: Fundamentals still carry risk: quarterly revenue was slightly down year‑over‑year even as EPS beat estimates, and Pfizer faces stiff competition in the GLP‑1/weight‑loss space from larger early movers—both could cap upside if execution or pricing weakens.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.